| Characteristics | QRESEARCH validation cohort | THIN validation cohort | ||||
| Men(n = 301 622) | Women(n = 306 111) | Men(n = 529 813) | Women (n = 542 987) | |||
| Age at baseline, median (interquartile range) | 47 (40 to 57) | 49 (41 to 59) | 48 (40 to 57) | 49 (41 to 59) | ||
| Body mass index (kg/m2), mean (SD) | 26.5 (4.0) | 26.1 (4.8) | 26.6 (4.0) | 26.1 (4.9) | ||
| Systolic blood pressure (mm Hg), mean (SD) | 135.3 (19.6) | 132.2 (21.6) | 135.6 (19.4) | 132.1 (21.0) | ||
| Total serum cholesterol (mmol), mean (SD) | 5.7 (1.1) | 5.8 (1.2) | 5.7 (1.1) | 5.8 (1.2) | ||
| HDL (mmol/l), mean (SD) | 1.3 (0.4) | 1.6 (0.4) | 1.3 (0.4) | 1.6 (0.4) | ||
| Total serum cholesterol/HDL ratio, mean (SD) | 4.5 (1.3) | 3.9 (1.2) | 4.5 (1.3) | 3.9 (1.2) | ||
| Current smoker | 84 930 (28.2) | 70 210 (22.9) | 141 113 (26.6) | 124 094 (22.9) | ||
| Family history of coronary heart disease in first-degree relative under 60 years | 27 829 (9.2) | 38 026 (12.4) | 18 638 (3.5) | 22 922 (4.2) | ||
| Receiving antihypertensive treatment* | 24 245 (8.0) | 36 992 (12.1) | 35 066 (6.6) | 56 886 (10.5) | ||
| Receiving ACE inhibitors* | 6 898 (2.3) | 7 170 (2.3) | 11 718 (2.2) | 12 901 (2.4) | ||
| Receiving β-blockers* | 11 321 (3.8) | 17 892 (5.8) | 16 700 (3.2) | 27 554 (5.1) | ||
| Receiving calcium channel blockers* | 7 346 (2.4) | 8 479 (2.8) | 9 847 (1.9) | 11 147 (2.1) | ||
| Receiving thiazides* | 6 837 (2.3) | 14 571 (4.8) | 10 630 (2.0) | 23 391 (4.3) | ||
Results are shown as counts (%) unless otherwise specified.
Patients receiving statins at baseline have been excluded.
*At entry to the cohort.